R&D efficiency of leading pharmaceutical companies : a 20-year analysis
- Comparative analysis of the R&D efficiency of 14 leading pharmaceutical companies for the years 1999–2018 shows that there is a close positive correlation between R&D spending and the two investigated R&D output parameters, approved NMEs and the cumulative impact factor of their publications. In other words, higher R&D investments (input) were associated with higher R&D output. Second, our analyses indicate that there are "economies of scale" (size) in pharmaceutical R&D.
| Author of HS Reutlingen | Kandelbauer, Andreas; Schuhmacher, Alexander |
|---|---|
| DOI: | https://doi.org/10.1016/j.drudis.2021.05.005 |
| ISSN: | 1359-6446 |
| Erschienen in: | Drug discovery today |
| Publisher: | Elsevier |
| Place of publication: | Amsterdam |
| Document Type: | Journal article |
| Language: | English |
| Publication year: | 2021 |
| Tag: | R&D efficiency; big pharma; economies of scale; pharmaceutical R&D |
| Volume: | 26 |
| Issue: | 8 |
| Page Number: | 6 |
| First Page: | 1784 |
| Last Page: | 1789 |
| DDC classes: | 610 Medizin und Gesundheit |
| Open access?: | Nein |
| Licence (German): |  In Copyright - Urheberrechtlich geschützt |
